X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Glenmark Pharma with Panacea Biotech - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs PANACEA BIOTECH - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA PANACEA BIOTECH GLENMARK PHARMA/
PANACEA BIOTECH
 
P/E (TTM) x 13.6 80.0 17.0% View Chart
P/BV x 3.8 1.8 215.0% View Chart
Dividend Yield % 0.3 0.0 -  

Financials

 GLENMARK PHARMA   PANACEA BIOTECH
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-16
PANACEA BIOTECH
Mar-14
GLENMARK PHARMA/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs1,262149 848.7%   
Low Rs67282 815.9%   
Sales per share (Unadj.) Rs270.684.1 321.5%  
Earnings per share (Unadj.) Rs24.9-18.3 -135.9%  
Cash flow per share (Unadj.) Rs34.4-6.7 -513.7%  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.20-  
Book value per share (Unadj.) Rs151.383.7 180.8%  
Shares outstanding (eoy) m282.1661.25 460.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.61.4 260.3%   
Avg P/E ratio x38.9-6.3 -616.0%  
P/CF ratio (eoy) x28.1-17.2 -162.9%  
Price / Book Value ratio x6.41.4 463.0%  
Dividend payout %8.00-   
Avg Mkt Cap Rs m272,7787,074 3,855.9%   
No. of employees `00010.02.8 364.5%   
Total wages/salary Rs m13,7821,449 951.0%   
Avg. sales/employee Rs Th7,614.91,874.1 406.3%   
Avg. wages/employee Rs Th1,374.8527.0 260.9%   
Avg. net profit/employee Rs Th700.2-407.7 -171.7%   
INCOME DATA
Net Sales Rs m76,3405,154 1,481.3%  
Other income Rs m356100 356.9%   
Total revenues Rs m76,6965,254 1,459.9%   
Gross profit Rs m14,172-766 -1,849.4%  
Depreciation Rs m2,691711 378.5%   
Interest Rs m1,7891,503 119.0%   
Profit before tax Rs m10,048-2,881 -348.8%   
Minority Interest Rs m011 0.0%   
Prior Period Items Rs m0-6 0.0%   
Extraordinary Inc (Exp) Rs m01,771 0.0%   
Tax Rs m3,02817 18,026.2%   
Profit after tax Rs m7,019-1,121 -626.0%  
Gross profit margin %18.6-14.9 -124.9%  
Effective tax rate %30.1-0.6 -5,167.9%   
Net profit margin %9.2-21.8 -42.3%  
BALANCE SHEET DATA
Current assets Rs m59,0963,810 1,551.0%   
Current liabilities Rs m40,0188,365 478.4%   
Net working cap to sales %25.0-88.4 -28.3%  
Current ratio x1.50.5 324.2%  
Inventory Days Days75156 48.2%  
Debtors Days Days11967 177.3%  
Net fixed assets Rs m39,07514,480 269.9%   
Share capital Rs m28261 460.4%   
"Free" reserves Rs m30,281903 3,353.0%   
Net worth Rs m42,7035,127 832.9%   
Long term debt Rs m24,8735,832 426.5%   
Total assets Rs m111,02619,433 571.3%  
Interest coverage x6.6-0.9 -721.9%   
Debt to equity ratio x0.61.1 51.2%  
Sales to assets ratio x0.70.3 259.3%   
Return on assets %7.92.0 403.9%  
Return on equity %16.4-21.9 -75.2%  
Return on capital %17.53.6 481.7%  
Exports to sales %43.324.5 176.5%   
Imports to sales %7.410.2 73.0%   
Exports (fob) Rs m33,0441,264 2,614.6%   
Imports (cif) Rs m5,672525 1,080.8%   
Fx inflow Rs m36,9451,539 2,400.3%   
Fx outflow Rs m61,066942 6,482.6%   
Net fx Rs m-24,122597 -4,039.1%   
CASH FLOW
From Operations Rs m3,449599 575.5%  
From Investments Rs m-8,802-438 2,010.0%  
From Financial Activity Rs m6,986-303 -2,308.7%  
Net Cashflow Rs m934-141 -660.9%  

Share Holding

Indian Promoters % 48.3 74.5 64.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 6.9 0.6 1,150.0%  
FIIs % 34.4 1.3 2,646.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 23.6 44.5%  
Shareholders   56,727 10,259 552.9%  
Pledged promoter(s) holding % 0.0 35.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   ALEMBIC LTD  SUN PHARMA  PIRAMAL ENTERPRISES  FDC LTD.  SHASUN PHARMA  

Compare GLENMARK PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Strong Note; Bank & Realty Stocks Rally(Closing)

Indian share markets surged further in the afternoon session and finished in the green for the second straight session on heavy buying in realty stocks, metal stocks and bank stocks.

Related Views on News

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

Dear PM Modi, India is Already Land of Self-Employed, and It Ain't Working(Vivek Kaul's Diary)

Aug 21, 2017

Most Indians who cannot find jobs, look at becoming self-employed.

It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

Aug 16, 2017

The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

Think Twice Before You Keep Money In A Savings Bank Account(Outside View)

Aug 22, 2017

Post demonetisation, a cut in bank savings deposits rates was in the offing.

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Aug 23, 2017 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 8-QTR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS